Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
about
Long-term drug treatment for obesity: a systematic and clinical reviewLong-term effects of weight-reducing drugs in people with hypertensionCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityWeight management in obesity - past and presentTreating morbid obesity in cirrhosis: A quest of holy grailAdvances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert ForumThe New Era of Drug Therapy for Obesity: The Evidence and the ExpectationsObesity pharmacotherapy: current perspectives and future directionsThe rise of multiple imputation: a review of the reporting and implementation of the method in medical researchCan medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies.Current and emerging medications for overweight or obesity in people with comorbiditiesEfficacy comparison of medications approved for chronic weight managementNext generation of weight management medications: implications for diabetes and CVD riskAntiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term managementWeight Loss Pharmacotherapy: Brief Summary of the Clinical Literature and Comments on Racial DifferencesObesity-Associated Hypertension: the Upcoming Phenotype in African-American Women.Obesity: Current and potential pharmacotherapeutics and targets.Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity.New and emerging drug molecules against obesity.Antiobesity pharmacotherapy: new drugs and emerging targetsOptimal Pharmacologic Treatment Strategies in Obesity and Type 2 DiabetesPharmacotherapy of Obesity: Clinical Trials to Clinical Practice.Treatment of hypertension in obese patients.Pharmacological inhibition of mitochondrial carbonic anhydrases protects mouse cerebral pericytes from high glucose-induced oxidative stress and apoptosis.Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesityA systematic review and narrative synthesis of interventions for uncomplicated obesity: weight loss, well-being and impact on eating disorders.Bariatric endocrinology: principles of medical practice.Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implicationsThe burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.Neurobiology of food intake in health and disease.Filling the treatment gap in the weight management of overweight and obese patients.Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approachAn evolving scientific basis for the prevention and treatment of pediatric obesityNew options for the treatment of obesity and type 2 diabetes mellitus (narrative review)A complications-based clinical staging of obesity to guide treatment modality and intensity.American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.Managing overweight and obesity in adults to reduce cardiovascular disease risk.
P2860
Q22253010-1E125C97-91AB-49BF-8695-794CED1F43C0Q24186054-256C7C2B-A330-46DB-8034-B5CB973A5850Q26740253-2D2F44EE-9CB6-4E78-BE97-568359578B52Q26765609-56EFCE81-CF72-4C2D-AF06-A1BB04C2CE19Q26774747-AE12E249-CE60-4214-8FA2-FC2BF0D2596FQ26775811-B2C8D98D-D339-407F-9A42-62C14362BA75Q26784022-720D6A14-19F6-4144-B00C-AEE1C049DEA3Q26827555-7B5BBCB3-4A6D-415B-BC11-CB0D41F750A2Q26828559-8451F720-3446-4360-8C69-358B0C4C3374Q26828889-2C837825-2C10-42CD-9ED0-9354ECAB44FEQ27015789-EC2ABDC9-0202-4B87-A6DC-D404698C2FC6Q27331844-CA39D7F8-FB35-4699-866B-DA76562A055FQ28080825-D4526DC9-7DF5-4498-A8ED-F0F5871F26F2Q28081944-3A93AC17-2351-4E20-9590-986EAEE4ECFEQ28082858-472EB9CD-3493-4240-88F4-73A7EFB6FB9AQ28084337-C5D776ED-4F17-4D6C-B37C-A2E4A4E7D73CQ28088815-BFC271DA-9AE4-40E1-ABA1-222217A8CE8DQ30234618-5AE162DA-5779-4687-A2B5-77832AADD898Q30243992-7B9848B9-3889-4521-A53F-F93D5FDE6098Q30250304-AB891373-C615-4EBC-BF9E-8AA7B1A122E3Q30353872-3C9C429B-FE4D-40FC-BF96-E3AC569321F7Q30354242-0D22FFF7-99EF-409F-A976-948C3FBC5D96Q30377441-39305B25-FA90-496B-9102-E4FEC3EEEB62Q30400748-68A3A5F2-D2AD-493C-A313-F2DCCCD283A5Q30429298-B92FBC50-F747-466B-9F4A-11A31C29C30DQ30536859-8324B3CA-1511-451A-BA2B-C9EA361DE50BQ33572190-E5A15908-FED1-4F61-9727-BA12725C089AQ33619779-01CFFE27-3D26-4434-A88E-D01CEE3AF4D2Q33677790-2C67F488-7D64-40EA-AA6D-E7575687D70CQ33717424-B6E47106-0F22-4732-93E2-E00CB9F7411AQ33750634-C131B564-1E2B-439A-B43B-F8C2B691AED5Q33825213-8C4D58C5-636E-471F-B3A2-34EDFD8BA94FQ33873328-35E12C84-FEC4-4748-839D-601E2B14D6DAQ33890570-483A0541-A879-44E8-93D0-F7C486C0139EQ33938171-4D8B8E2C-A195-46A3-B682-B83302F2A240Q34028763-79564D37-EC20-4FD3-A7F2-D42E849C373DQ34070610-9FCA46A6-404A-4B12-8CC0-D3BCCC2C2F54Q34070626-D8654901-2107-4E7B-9FD8-FC6A6C3967B5Q34081331-926E9417-0AFD-4044-9CA5-DD0B46447E4CQ34106367-CE8DD73F-672A-4979-B2D8-8C45BB1FBE64
P2860
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Effects of low-dose, controlle ...... ebo-controlled, phase 3 trial.
@en
Effects of low-dose, controlle ...... ebo-controlled, phase 3 trial.
@nl
type
label
Effects of low-dose, controlle ...... ebo-controlled, phase 3 trial.
@en
Effects of low-dose, controlle ...... ebo-controlled, phase 3 trial.
@nl
prefLabel
Effects of low-dose, controlle ...... ebo-controlled, phase 3 trial.
@en
Effects of low-dose, controlle ...... ebo-controlled, phase 3 trial.
@nl
P2093
P921
P1433
P1476
Effects of low-dose, controlle ...... ebo-controlled, phase 3 trial.
@en
P2093
Barbara Troupin
Craig A Peterson
Kishore M Gadde
Michael L Schwiers
Wesley W Day
P304
P356
10.1016/S0140-6736(11)60205-5
P407
P577
2011-04-08T00:00:00Z